1. Home
  2. Products
  3. Customized FluoroAb™
  4. RTN4
  5. Anti-RTN4 MAb (Clone 2)-iFluor® 546 Succinimidyl Ester

Anti-RTN4 MAb (Clone 2)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14531)

This product is comprised of an Humanized Anti-RTN4 IgG1 antibody (Clone 2) labeled with iFluor® 546 Succinimidyl Ester. iFluor® 546 Succinimidyl Ester is a Green-fluorescent dye and it's excitation/emission is 403/427 nm.

  • TARGET
  • ANTIBODY
  • DYE
  • Name
  • RTN4
  • Alternative Names
  • RTN-X
  • Overview
  • Reticulon 4, also known as neurite outgrowth inhibitor or Nogo, is a protein encoded by the RTN4 gene in humans and has been identified as a neurite outgrowth inhibitor unique to the central nervous system . During nerve development, Nogo is mainly expressed by neurons and provides inhibitory signals for the migration and germination of CNS endothelial (tip) cells, thereby limiting the density of blood vessels. There are three isoforms: Nogo A, B and C. Nogo-A has two known inhibitory domains, including the N-terminal amino Nogo and Nogo-66, the latter constituting the molecular extracellular loop. Both Amino-Nogo and Nogo-66 are involved in the inhibition reaction, of which Amino-Nogo is a strong inhibitor of neurite outgrowth, and Nogo-66 is involved in the destruction of the growth cone.

    Studies have shown that blocking Nogo-A during neuronal damage (from diseases such as multiple sclerosis) can help protect or restore damaged neurons. [9] The study of the mechanism of this protein provides great potential for the treatment of autoimmune-mediated demyelinating diseases and spinal cord injury regeneration. It has also been found that it is a key participant in this process, and physical exercise can enhance the learning and memory processes of the brain. also shows that Nogo-A has a negative regulatory effect on blood vessel growth and repair after ischemic stroke. In the experimental stroke mouse model, Nogo-A gene deletion and antibody-mediated blockage resulted in enhanced revascularization and functional recovery. In addition, anti-Nogo-A antibody treatment reduces vascular leakage, the main complication after stroke.
  • Overview
  • Humanized Anti-RTN4 IgG1 antibody (Clone 2)
  • Species Reactivity
  • Human
  • Name
  • iFluor® 546 Succinimidyl Ester
  • Color
  • Green
  • Excitation⁄Emission (nm)
  • 541/557
  • Detection method
  • Fluorescent

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for WJY0-LS14531. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target
CAT# Product Name Linker Payload
ADC-W-1741 Anti-RTN4 (Atinumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-1744 Anti-RTN4 (Ozanezumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-1743 Anti-RTN4 (Ozanezumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-1746 Anti-RTN4 (Ozanezumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-1745 Anti-RTN4 (Ozanezumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.